Stage I nonseminomatous germ cell tumor of the testis: more questions than answers?

Thomas Powles

doi:10.1016/j.hoc.2011.03.013

Stage I nonseminomatous germ cell tumor of the testis: more questions than answers?

Hematol Oncol Clin North Am. 2011 Jun;25(3):517-27,viii. doi: 10.1016/j.hoc.2011.03.013.

Author

Thomas Powles¹

Affiliation

¹ St Bartholomew's Hospital, Barts and The London NHS Trust, Charterhouse Square, London EC1A7BE, UK. Thomas.Powles@bartsandthelondon.nhs.uk

PMID: 21570606
DOI: 10.1016/j.hoc.2011.03.013

Abstract

The outcome of patients with stage I nonseminomatous germ cell tumors (NSGCTs) is excellent, with 99% overall 5-year survival. If treated with orchiectomy alone, approximately 30% of patients relapse with metastatic disease. Therefore adjuvant therapy with either chemotherapy or retroperitoneal lymph node dissection (RPLND) is often recommended, despite impressive results with active surveillance alone. This article addresses the risks and benefits of each approach.

Publication types

Review

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Chemotherapy, Adjuvant
Humans
Lymph Node Excision
Male
Neoplasm Staging
Neoplasms, Germ Cell and Embryonal / drug therapy
Neoplasms, Germ Cell and Embryonal / pathology
Neoplasms, Germ Cell and Embryonal / surgery*
Orchiectomy*
Retroperitoneal Space
Testicular Neoplasms / drug therapy
Testicular Neoplasms / pathology
Testicular Neoplasms / surgery*

Supplementary concepts

Nonseminomatous germ cell tumor